TM Editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Image Source: Unsplash
 

Based in Belgium, Sequana Medical develops and commercializes products to treat diuretic-resistant fluid overload, a frequent complication of liver disease and heart failure. Its proprietary alfapump and DSR approaches aim to provide significant clinical and quality-of-life benefits in these fluid overload conditions. In this interview, CEO Ian Crosbie describes how the alfapump may provide material benefits for patients with recurrent and refractory ascites as shown in pivotal data from its POSEIDON North American registration study, with US market approval projected before the end of 2024. Crosbie highlights the promising results shown so far for its DSR 2.0 product in patients with persistent congestion due to heart failure, including from the recent non-randomized cohort of its US MOJAVE Phase I/IIa study, and he discusses the next steps ahead for this program.

Video Length: 00:25:42

More By This Author:

Media And Games Invest: Full Year Prospects
Incannex Healthcare: Is Life Better On Nasdaq?
Digital Healthcare: Leveraging Data And AI